Search
An experimental brain injury medication conceived in laboratories at UT Health San Antonio was tested Tuesday, June 14, in the first human subject. If the drug, called AST-004, performs well in human studies, it will be an urgently needed and novel treatment for stroke and traumatic brain injury victims, including those with concussions.
Drs. Ruben Mesa, Kate Lathrop and Mark Bonnen of the Mays Cancer Center took part in a panel discussion for this story. Read More
Dr. James Lechleiter, Cell Systems and Anatomy, is featured in this story. Read More
Dr. Mandie Svatek, Pediatrics, was interviewed for this story. Read More
James D. Lechleiter, PhD, professor of cell systems and anatomy at UT Health San Antonio, and Andrea Giuffrida, PhD, vice president for strategic industry ventures at UT Health San Antonio, were quoted in this story about the first human test of experimental brain injury medication conceived in laboratories at UT Health San Antonio. Read More
Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 15, 2022) — Pheo Para Alliance, a patient advocacy organization dedicated to supporting those with pheochromocytoma (pheo) and paraganglioma (para), a rare neuroendocrine tumor, has designated The University of Texas Health Science Center at San Antonio (UT Health San Antonio) as a Pheo Para Center of Excellence. The […]
Dr. Fred Campbell, Medicine, is quoted in this article. Read More
Dr. Jessica Sandoval and Dr. Christopher Wallace, Psychiatry and Behavioral Sciences, were quoted in this story. Read More
Dr. Alan Peterson, Psychiatry and Behavioral Science, was interviewed for this segment. Watch Video
Robert Svatek, MD, Urology, is quoted in this article. Read More